Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York.
Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Neuro Oncol. 2018 Apr 9;20(5):687-694. doi: 10.1093/neuonc/nox187.
There has been significant improvement in treatment outcomes of primary central nervous system lymphoma (PCNSL) at specialized centers over the past several decades; however, it is unclear if these changes have translated to benefits in the general population.
In this study, we utilized 2 national databases to examine survival trends over time for PCNSL: the Central Brain Tumor Registry of the United States (CBTRUS, 2000-2013) and 18 registries from the Surveillance, Epidemiology, and End Results program (SEER, 1973-2013).
The annual incidence of PCNSL in 2013 was 0.4 per 100000 population (CBTRUS/SEER). Incidence increased from 0.1 per 100000 in the 1970s to 0.4 per 100000 in the 1980s, correlating with an increase in the diagnosis of patients ≥70 years (1973: 0.2 vs 2013: 2.1 [SEER]). Incidence rates differed greatly between young and elderly patients (age 20-29 y: 0.08 vs 70-79 y: 4.32 [CBTRUS]). Even though the median overall survival of all patients doubled from 12.5 months in the 1970s to 26 months in the 2010s, this survival benefit was limited to patients <70 years. Survival in the elderly population has not changed in the last 40 years (6 mo in the 1970s vs 7 mo in the 2010s, P = 0.1).
The poor outcome seen in the particularly vulnerable elderly patient population highlights the need for clinical trials targeting the elderly in hopes of improving treatment strategies and survival.
在过去几十年里,专门中心的原发性中枢神经系统淋巴瘤(PCNSL)的治疗结果得到了显著改善;然而,尚不清楚这些变化是否对普通人群有益。
在这项研究中,我们利用两个国家数据库来研究 PCNSL 的时间生存趋势:美国中枢神经系统肿瘤登记处(CBTRUS,2000-2013 年)和监测、流行病学和最终结果计划(SEER,1973-2013 年)的 18 个登记处。
2013 年 PCNSL 的年发病率为每 10 万人中 0.4 例(CBTRUS/SEER)。发病率从 20 世纪 70 年代的每 10 万人 0.1 例增加到 20 世纪 80 年代的每 10 万人 0.4 例,与 70 岁以上患者诊断的增加相关(1973 年:0.2 比 2013 年:2.1 [SEER])。年轻和老年患者的发病率差异很大(年龄 20-29 岁:0.08 比 70-79 岁:4.32 [CBTRUS])。尽管所有患者的中位总生存期从 20 世纪 70 年代的 12.5 个月增加到 2010 年代的 26 个月,但这种生存获益仅限于<70 岁的患者。在过去的 40 年中,老年患者的生存没有改变(20 世纪 70 年代为 6 个月,2010 年代为 7 个月,P=0.1)。
在特别脆弱的老年患者群体中看到的不良预后突出表明,需要针对老年人进行临床试验,以期改善治疗策略和生存。